The Delegation from African Medicines Agency, African Medicines Quality Forum and Bill & Melinda Gates Foundation Visited BIBP

On July 2^nd,2023, Mr. Michel Sidibé, Envoy of African Medicines Agency (AMA), Mr. Bonaventure Chilinde, Chairperson of African Medicines Quality Forum (AMQF), and Xu Fujie and Yang Jianyue, Deputy Director of the Beijing Representative Office of Bill & Melinda Gates Foundation, and others, for total 7 people visited Sinopharm CNBG, Beijing Institute of Biological Products Co.,Ltd. (hereinafter referred to as "BIBP"). Zhang Yuntao, Chief Scientist of Sinopharm and Vice President of CNBG, Li Meng, Director of International Cooperation Department of CNBG, Liu Zhaohui, Vice General Manager and relevant leaders of International Cooperation Department of BIBP met with the guests.

▲Mr. Michel Sidibé, Envoy of AMA, Mr. Bonaventure Chilinde, Chairperson of AMQF, and Xu Fujie and Yang Jianyue, Deputy Director of the Beijing Representative Office of Bill & Melinda Gates Foundation, and others, for total 7 people visited BIBP.

Zhang Yuntao expressed his warm welcome to the guests, and said that at present, CNBG has more cooperation with many African countries in terms of product export and clinic, for example, BIBP’s Inactivated COVID-19 Vaccine (Vero Cell) were exported to Africa in large quantities through COVAX during the COVID-19 pandemic to fight it with the African people; Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell, Oral) (bOPV) and Poliomyelitis Vaccine (Vero Cell) (Inactivated, Sabin Strains) (sIPV) have passed the pre-qualification of WHO, and have obtained registration certificates in some African countries and realized export, while continuing to register in more African countries; Moreover, many key products of CNBG are also carrying out clinical trials in Africa successively. CNBG will continue to cooperate with Africa in R&D, tech-transfer and regulatory aspects. In addition, CNBG and Bill & Melinda Gates Foundation have always had profound cooperation, and look forward to more in-depth exchanges and cooperation on better programs in the future.

Subsequently, Li Meng introduced CNBG and BIBP in terms of the company's history, product portfolio, manufacturing campus, R&D pipeline, and contribution to global public health, etc. 

▲Address by Mr. Michel Sidibé, Envoy of AMA

▲Addressed by Mr. Bonaventure Chilinde, Chairperson of AMQF

The African side respectively elaborated on the current challenges in R&D, market regulation and other aspects, expressing the hope for more in-depth exchanges and cooperation, introducing more R&D technologies and training into Africa, and enhancing localized R&D and production capacity; hoping that China can provide assistance and support to enhance the regulatory ability of Africa, and expressing the hope to take advantage of the diversity of the population in Africa to proactively participate in the global clinical layout and make greater contributions to human health. Zhang Yuntao said that the possibilities of R&D and clinical cooperation will be fully explored, and that the cooperation between the two sides will have great potential and broad prospects.

▲Visit to China Museum of Biology

The guests also visited the laboratories in R&D building, the bOPV workshop and China Museum of Biology.